Skip to main content
Premium Trial:

Request an Annual Quote

MGI Tech Inks Nordic Distribution Deal With AddLife

NEW YORK — Chinese sequencing instrument and reagent maker MGI Tech said on Thursday that it has signed a distribution agreement for its products in Nordic markets with AddLife.

Under the terms of the deal, Stockholm-based AddLife will offer MGI's products through four of its Triolab Group subsidiaries, which distribute life science products in Sweden, Norway, Denmark, Iceland, and Finland.

Financial and other terms were not disclosed.

Earlier this year, MGI Tech expanded the availability of its sequencing platform portfolio to several additional European nations — none of which are covered under the deal with AddLife — after the European Patent Office Board of Appeal invalidated a patent held by Illumina.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.